Clinical Trial Update: Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating CB-839 (telaglenastat) in combination with panitumumab and irinotecan for metastatic or refractory colorectal cancer; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• CB-839 (telaglenastat)
• Irinotecan (Irinotecan)
• Panitumumab (panitumumab)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Colorectal Cancer, Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-08-30